NCT04888793

Immune Response to Anti COVID-19 Vaccine in Immunocompromised Patients: a Cohort Study

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 260 (actual)
• Sponsor: Pontificia Universidad Catolica de Chile · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

Despite COVID-19 pandemic having started more than one year ago, there are still limited treatment options for these patients, and over 145 million cases and 3 millions deaths have ensued worldwide. Fortunately, SARSCoV2 vaccines have been developed at an unprecedented pace. While the vaccination programs are still ongoing, early reports on efficacy are mainly centered on healthy population. In Chile most people have received the inactivated Coronavac vaccine. Data on the immune response after vaccination in immunocompromised patients is lacking. Therefore, this study aims to evaluate the immune response after Coronavac vaccine in 5 cohorts of immunocompromised patients and healthy controls. We will include patients with cancer, HIV, solid organ transplant and patients receiving immunomodulatory agents for rheumatic diseases.

Conditions

• Covid19
• COVID-19 Vaccines

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	Serologic immune response evaluation	Detection of total and neutralizing antibodies against SARS-CoV-2

Timeline

• Start date: 2021-05-12
• Primary completion: 2021-09-01
• Completion: 2021-11-01
• First posted: 2021-05-17
• Last updated: 2021-11-16

Locations

1 site across 1 country: Chile